The therapeutic potential of interleukin-6 in treating obesity

Bibliography

• CALLE EE, RODRIGUEZ C,WALKER-THURMOND K, THUN MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US Adults. N Engl. I Med. (2003) 348:1625–1638.
   PubMed Web of Science ®Google Scholar
• ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414:782–787.
   PubMed Web of Science ®Google Scholar
• GURA T: Obesity drug pipeline not so fat.Science (2003) 299:849–852.
   PubMed Web of Science ®Google Scholar
• MOHAMED-ALI V, GOODRICK S,RAWESH A et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. Clin. Endocrinol Metal,. (1997) 82:4196–4200.
   Google Scholar
• •Original paper showing that human adipose tissue secrets IL-6.
   Google Scholar
• PEDERSEN BK, STEENSBERG A, SCHJERLING P: Muscle-derived interleukin-6: possible biological effects. Physiol (2001) 536:329–337.
   Web of Science ®Google Scholar
• LYNGSO D, SIMONSEN L, BULOW J: Interleukin-6 production in human subcutaneous abdominal adipose tissue: The effect of exercise. Physiol (2002) 543:373–378.
   Web of Science ®Google Scholar
• WALLENIUS V, WALLENIUS K, AHREN B et a/.: Interleuldn-6-deficient mice develop mature-onset obesity. Nat. Med. (2002) 8:75–79.
   Google Scholar
• •Shows that lack of IL-6 causes obesity in mice.
   Google Scholar
• FERNANDEZ-REAL JM, RICART W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev (2003) 24:278–301.
   PubMed Web of Science ®Google Scholar
• BASTARD JP, JARDEL C, BRUCKERT Eet al: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Clin. Endocrinol Metal,. (2000) 85:3338–3342.
   PubMed Web of Science ®Google Scholar
• HIRANO T: Interleukin 6 and its receptor:ten years later. hat. Rev Immunol (1998) 16:249–284.
   PubMed Web of Science ®Google Scholar
• HEINRICH PC, BEHRMANN I, MULLER-NE WENG, SCHAPER F, GRAEVE L: Interleuldn-6-type cytokine signalling through the gp130/jak/stat pathway. Biochem. j. (1998) 334(Pt 2):297–314.
   PubMed Web of Science ®Google Scholar
• GLOAGUEN I, COSTA P, DEMARTIS A et al.: Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. USA (1997) 94:6456–6461.
   PubMed Web of Science ®Google Scholar
• LAMBERT PD, ANDERSON KD, SLEEMAN MW et al: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA (2001) 98:4652–4657.
   PubMed Web of Science ®Google Scholar
• BRAY GA, TARTAGLIA LA: Medicinal strategies in the treatment of obesity. Nature (2000) 404:672–677.
   PubMed Web of Science ®Google Scholar
• SLEEMAN MW, ANDERSON KD, LAMBERT PD, YANCOPOULOS GD, WIEGAND SJ: The ciliary neurotrophic factor and its receptor, CNTFR alpha. Flamm. Acta Helv. (2000) 74:265–272.
   PubMedGoogle Scholar
• ESPAT NJ, AUFFENBERG T, ROSENBERG JJ et al.: Ciliary neurotrophic factor is catabolic and shares with il-6 the capacity to induce an acute phase response. Am. J. Physiol (1996) 271:R185–R190.
   Google Scholar
• BJORBAEK C, ELMQUIST JK, EL-HASCHIMI K et al: Activation of socs-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Endocrinology (1999) 140:2035–2043.
   PubMed Web of Science ®Google Scholar
• SCHOBITZ B, VOORHUIS DA,DE KLOET ER: Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Neurosci. Lett. (1992) 136:189–192.
   PubMed Web of Science ®Google Scholar
• SHIZUYA K, KOMORI T, FUJI WARA Ret al.: The expressions of mRNAs for interleukin-6 (IL-6) and the IL-6 receptor (IL-6r) in the rat hypothalamus and midbrain during restraint stress. Life Sci. (1998) 62:2315–2320.
   Google Scholar
• WALLENIUS K, WALLENIUS V, SUNTER D, DICKSON SL,JANSSON JO: Intracerebroventricular interleukin-6 treatment decreases body fatin rats. Biochem. Biophys. Res. Commun. (2002) 293:560–565.
   PubMed Web of Science ®Google Scholar
• VAN SNICK J: Interleukin-6: an overview. Ann. Rev Immunol (1990) 8:253–278.
   PubMed Web of Science ®Google Scholar
• KOPF M, BAUMANN H, FREER G et al: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368:339–342.
   PubMed Web of Science ®Google Scholar
• XING Z, GAULDIE J, COX G et al: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Gin. Invest. (1998) 101:311–320.
   PubMed Web of Science ®Google Scholar
• •Paper showing that IL-6 has potent anti-inflammatory function in addition to its acute phase promoting effect.
   Google Scholar
• STARKIE R, OSTROWSKI SR, JAUFFRED S, FEBBRAIO M, PEDERSEN BK: Exercise and IL-6 infusion inhibit endotwdn-induced TNF-alpha production in humans. FASEB (2003) 17:884–886.
   PubMed Web of Science ®Google Scholar
• STEENSBERG A, FISCHER CP, KELLER C, MOLLER K,PEDERSEN BK: IL-6 enhances plasma IL-lra, IL-10, and cortisol in humans. Am. J. Physiol Endocrinol Metab (2003) 285:E433–E437.
   Google Scholar
• VAN HALL G, STEENSBERG A, SACCHETTI M et al.: Interleuldn-6 stimulates lipolysis and fat oxidation in humans. I Clin. EndocrinoL Metab. (2003) 88:3005–3010.
   PubMed Web of Science ®Google Scholar
• CHROUSOS GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N EngL I Med. (1995) 332:1351–1362.
   PubMed Web of Science ®Google Scholar
• VGONTZAS AN, PAPANICOLAOU DA, BIXLER EO et al.: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol Metab. (1997) 82:1313–1316.
   PubMed Web of Science ®Google Scholar
• •Paper showing that serum IL-6 correlates positively with fat mass in humans.
   Google Scholar
• ORBAN Z, REMALEY AT,SAMPSON M, TRAJANOSKI Z, CHROUSOS GP: The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. I Clin. Endocrinol Metab. (1999) 84:2126–2133.
   PubMed Web of Science ®Google Scholar
• FASSHAUER M, KLEIN J, LOSSNER U,PASCHKE R: Interleuldn (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3t3-11adipocytes. Horm. Metab. Res. (2003) 35:147–152.
   PubMed Web of Science ®Google Scholar
• FLOWER L, GRAY R, PINKNEY J, MOHAMED-ALI V: Stimulation of interleukin-6 release by interleukin- lbeta from isolated human adipocytes. Cytokine (2003) 21:32–37.
   PubMed Web of Science ®Google Scholar
• OSTROWSKI K, ROHDE T, ASP S, SCHJERLING P, PEDERSEN BK: Pro-and anti-inflammatory cytokine balance in strenuous exercise in humans,/ Physiol (1999) 515:287–291.
   Google Scholar
• •Study showing a 100-fold increase in circulating IL-6 levels after strenuous physical exercise.
   Google Scholar
• JONSDOTTIR IH, SCHJERLING P, OSTROWSKI K et al: Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. J. PhysioL (2000) 528(Pt 1):157–163.
   PubMed Web of Science ®Google Scholar
• KELLER C, STEENSBERG A, PILEGAARD H et al: Transcriptional activation of the il-6 gene in human contracting skeletal muscle: Influence of muscle glycogen content. FASEB. (2001) 15:2748–2750.
   PubMed Web of Science ®Google Scholar
• LUO G, HERSHKO DD, ROBB BW, WRAY CJ, HASSELGREN PO: IL-lbeta stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-kappa B. Am. I PhysioL Regal. Integc Comp. Physiol (2003) 284:R1249–R1254.
   Google Scholar
• SCHOBITZ B, DE KLOET ER, SUTANTO W, HOLSBOER F: Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur: Neurosci. (1993) 5:1426–1435.
   PubMed Web of Science ®Google Scholar
• CRESSMAN DE, GREENBAUM LE, DEANGELIS RA et al: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (1996) 274:1379–1383.
   PubMed Web of Science ®Google Scholar
• WALLENIUS V, WALLENIUS K, JANSSON JO: Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL 6( / )) mice. J. HepatoL (2000) 33:967–974.
   PubMed Web of Science ®Google Scholar
• WALLENIUS V, WALLENIUS K, HISAOKA M et al: Retarded liver growth in interleukin-6-deficient and tumor necrosis factor receptor-l-deficient mice. Endocrinology (2001) 142:2953–2960.
   PubMed Web of Science ®Google Scholar
• JONES SA, ROSE-JOHN S: The role ofsoluble receptors in cytokine biology: the agonistic properties of the sIL-6r/IL-6 complex. Biochim. Biophys. Acta (2002) 1592:251–263.
   PubMed Web of Science ®Google Scholar
• FLIER JS, FOSTER DW: Eating disorders: obesity, anorexia nervosa, and bulimia nervosa. In: Williams Textbook of Endocrinology (9th ed), Williams RH, Wilson JD, Foster DW, Kronenberg HM & Larsen PR (Eds), Saunders, (1998):1061–1097.
   Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, WOODS SC, PORTE D JR, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661–671.
   PubMed Web of Science ®Google Scholar
• GAO Y, NG YK, LIN JY, LING EA: Expression of immunoregulatory cytokines in neurons of the lateral hypothalamic area and amygdaloid nuclear complex of rats immunized against human IGg. Brain Res. (2000) 859:364–368.
   PubMed Web of Science ®Google Scholar
• WANG W, LONNROTH C,SVANBERG E, LUNDHOLM K: Cytokine and cyclooxygenase-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia. Cancer Res. (2001) 61:4707–4715.
   PubMed Web of Science ®Google Scholar
• MIYAHARA S, KOMORI T,FUJI WARA R et al.: Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci. (2000) 66:PL93-PL98.
   Google Scholar
• NIIMI M, WADA Y, SATO M,TAKAHARA J, KAWANISHI K: Effect of continuous intravenous injection of interleukin-6 and pretreatment with cyclooxygenase inhibitor on brain c-fos expression in the rat. Neuroendocrinology (1997) 66:47–53.
   PubMed Web of Science ®Google Scholar
• LI G, KLEIN RL, MATHENY M et al: Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience (2002) 115:879–889.
   PubMed Web of Science ®Google Scholar
• ROTHWELL NJ, BUSBRIDGE NJ, LEFEUVRE RA et al: Interleuldn-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. (1991) 69:1465–1469.
   PubMed Web of Science ®Google Scholar
• TSIGOS C, PAPANICOLAOU DA, DEFENSOR R et al.: Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energyexpenditure. Neuroendocrinology (1997) 66:54–62.
   PubMed Web of Science ®Google Scholar
• PRPIC V, WATSON PM,FRAMPTON IC et al.: Differential mechanisms and development of leptin resistance in a/j versus c5761/6j mice during diet-induced obesity. Endocrinology (2003) 144:1155–1163.
   Google Scholar
• COHEN P, MIYAZAKI M, SOCCI ND et al.: Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 297:240–243.
   PubMed Web of Science ®Google Scholar
• METZGER S, GOLDSCHMIDT N, BARASH V et al: Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am. Physiol. (1997) 273:E262–E267.
   Google Scholar
• METZGER S, HASSIN T, BARASH V, PAPPO O, CHAJEK-SHAUL T: Reduced body fat and increased hepatic lipid synthesis in mice bearing interleukin-6-secreting tumor. Am. I Physiol.Endocrinol. Metab. (2001) 281:E957–E965.
   Google Scholar
• ETTINGER WH JR, SUN WH, BINKLEY N, KOUBA E, ERSHLER W: Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. Cerontol A Biol. Sci. Med. Sci. (1995) 50:M137–M140.
   Google Scholar
• LYNGSO D, SIMONSEN L, BULOW J: Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. I Physiol. (2002) 543:379–386.
   PubMed Web of Science ®Google Scholar
• BRUUN JM, VERDICH C, TOUBRO S, ASTRUP A, RICHELSEN B: Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur. Endocrinol. (2003) 148:535–542.
   PubMed Web of Science ®Google Scholar
• STOUTHARD JM, ROMIJN JA, VAN DER POLL T et al: Endocrinologic and metabolic effects of interleukin-6 in humans. Am. J. Physiol. (1995) 268:E813–E819.
   Google Scholar
• TSIGOS C, PAPANICOLAOU DA, KYROU I et al.: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J. Clin. Endocrinol. Metab. (1997) 82:4167–4170.
   PubMed Web of Science ®Google Scholar
• SENN JJ, KLOVER PJ, NOWAK IA, MOONEY RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes (2002) 51:3391–3399.
   PubMed Web of Science ®Google Scholar
• FASSHAUER M, KRALISCH S, KLIER M et al.: Adiponectin gene expression and secretion is inhibited byinterleukin-6 in 3t3-11 adipocytes. Biochem. Biophys. Res. Commun. (2003) 301:1045–1050.
   PubMed Web of Science ®Google Scholar
• BRUUN JM, LIHN AS, VERDICH C et al.: Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and M vitro investigations in humans. Am. j Physiol. Endocrinol. Metab. (2003) 285:E527–E533.
   Google Scholar
• ENGELI S, FELDPAUSCH M, GORZELNIAK K et al.: Association between adiponectin and mediators of inflammation in obese women. Diabetes (2003) 52:942–947.
   PubMed Web of Science ®Google Scholar
• STEENSBERG A, FISCHER CP, SACCHETTI M et al.: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. I Physiol. (2003) 548:631–638.
   PubMed Web of Science ®Google Scholar
• KUBASZEK A, PIHLAJAMAKI J, PUNNONEN K et al: The c-174g promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes (2003) 52:558–561.
   PubMed Web of Science ®Google Scholar
• ••This study shows that IL-6 gene promoterpolymorphisms are correlated with basal metabolic rate and insulin sensitivity in healthy individuals.
   Google Scholar
• FISHMAN D, FAULDS G, JEFFERY R et al.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. I. Clin. Invest. (1998) 102:1369–1376.
   PubMed Web of Science ®Google Scholar
• KUBASZEK A, PIHLAJAMAKI J, KOMAROVSKI V et al.: Promoter polymorphisms of the TNF-alpha (g-308a) and IL-6 (c-174g) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish diabetes prevention study. Diabetes (2003) 52: 1872-1876.
   Google Scholar
• WERNSTEDT I, ERIKSSON A-L, SKRTIC S et al.: A common polymorphism in the interleukin-6 gene promoter is associated with increased risk of overweight. Obes. Res. (2003) (submitted).
   Google Scholar
• •This paper shows that a common IL-6 promoter polymorphism influences body mass index in humans.
   Google Scholar
• STENLOF K, WERNSTEDT I, FJALLMAN T et al: Interleuldn-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. I Clin. Endocrinol. Metab. (2003) 88(9):4379–4383. 1069Expert Op/n. Biol. Ther. (2003) 3(7)
   Google Scholar
• CARO JF, KOLACZYNSKI JW,NYCE MR et al: Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet (1996) 348:159–161.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, PESKIND E, RASKIND M, BOYKO EJ, PORTE D JR: Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. (1996) 2:589–593.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ,GUTIERREZ EG: Penetration of interleukin-6 across the murine blood-brain barrier. NeuroscL Lett. (1994) 179:53–56.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES SE, LUONG LA, OGG MS, HAWE E, MILLER GJ: The interleukin-6-174 g/c promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Ear. Heart J. (2001) 22:2243–2252.
   PubMed Web of Science ®Google Scholar
• BARSH GS, FAROOQI IS,O'RAHILLY S: Genetics of body-weight regulation. Nature (2000) 404:644–651.
   PubMed Web of Science ®Google Scholar
• SEINO Y, IKEDA U, IKEDA M et al.: Interleukin 6 gene transcripts are expressedin human atherosclerotic lesions. Cytokine (1994) 6:87–91.
   PubMed Web of Science ®Google Scholar
• ELHAGE R, CLAMENS S, BESNARD S et al.: Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by Hbeta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis (2001) 156:315–320.
   PubMed Web of Science ®Google Scholar
• •Unexpected finding that lack of IL-6 increased atherosclerosis in mice.
   Google Scholar
• JONES KG, BRULL DJ, BROWN LC et al.: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation (2001) 103:2260–2265.
   PubMed Web of Science ®Google Scholar
• GEORGES JL, LOUKACI V, POIRIER O et al.: Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude cas-temoin de finfarctus du myocarde. j MM. Med. (2001) 79:300–305.
   PubMed Web of Science ®Google Scholar
• HUBER SA, SAKKINEN P, CONZE D, HARDIN N, TRACY R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscier. a/MA V3SC. Biol. (1999) 19:2364–2367.
   Google Scholar
• VALEN G, YAN ZQ, HANSSON GK: Nuclear factor kappa-B and the heart. J. Am. Coll Cardiol (2001) 38:307–314.
   PubMed Web of Science ®Google Scholar
• WEBER JS: Clinical trials with IL-6. Ann. NY Acad. ScL (1995) 762:357–358.
   PubMed Web of Science ®Google Scholar
• WEBER J, GUNN H, YANG J et al.: A phase I trial of intravenous interleukin-6 in patients with advanced cancer. ImmunotheL Emphasis Tumor Immunol (1994) 15:292–302.
   PubMed Web of Science ®Google Scholar
• KOVALCHUK AL, KIM JS, PARK SS et al.: IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc. Natl. Acad. ScL USA (2002) 99:1509–1514.
   PubMed Web of Science ®Google Scholar
• http://www.regeneron.com Regeneron website.Affiliation
   Google Scholar